Genomic Medicine and Warfarin Dosing: Webcast

Steve Murphy at Helix Health is ready to organize the second webcast about genomic medicine. The first one focused on breast cancer and was fascinating.

Now they will focus on warfarin dosing. According to the American Food and Drug Administration, health care providers can use genetic tests to improve their initial estimate of what is a reasonable dose for patients (details here).

Helix Health, the first U.S. stand-alone genomic medicine practice, is hosting a 90-minute CliniCastTM this Monday, June 30, 2008  from 1:00-2:30 PM EDT to examine: How Genomic Medicine Improves the Accuracy of Warfarin Dosing

I encourage you to register here.

The topics they plan to cover:

  1. Why genetic testing is a necessary feature  in anticoagulant therapy.
  2. What potential risks exist in “Trial and Error” Dosing
  3. Will insurance cover this genetic testing?
  4. What are potential tort issues in predictive genetic testing and medical uses of genetic tests associated with anticoagulant therapy?
  5. Why aren’t physicians utilizing FDA approved testing and dosage guidance?

The speakers:

  • Steven A.R. Murphy, MD – Clinical Genetics Fellow at Yale School of Medicine, and Helix Health’s Managing Partner will moderate the panel.
  • Adam  J. Messenger, MD – Specializing in the fields of Pharmacogenomics and Pharmacogenetics, which strive to select the correct medication and the correct dosage of that medication based on an individual’s genetic blueprint. Currently on faculty at New York Medical College and at the Graduate School of Basic Medical Sciences in the Department of Pharmacology.
  • Glenn Gandelman, MD, MPH, FACC – Cardiologist specializing the diagnosis, prevention, and treatment of cardiovascular disease. Managing Partner, Gandelman Cardiology, PC, Greenwich, CT. Additional training in echocardiography and nuclear medicine. Board certified in Internal Medicine, Cardiology, Echocardiography, and Nuclear Cardiology.
  • Eric Johnson, PhD – Chief Science Officer Iverson Genetic Diagnostics, Inc. Director of the Neurovascular/Epilepsy Genetics Research Laboratory at the Barrow Neurological Institute (BNI) in Phoenix, AZ and as Founding Director of the clinical Molecular Diagnostics and BioBanking Laboratories at PreventionGenetics in Marshfield, WI.
  • Gary E. Marchant – PhD, JD, Lincoln Professor of Emerging Technologies, Law & Ethics, Sandra Day O’Connor College of Law; Executive Director, Center for Law, Science & Technology, Professor, School of Life Sciences Arizona State University.